Isomorphic Labs is approaching a major test for AI-driven drug discovery: moving drugs designed with AlphaFold-based AI models into its first human trials.
The company, a Deepmind spin-off focused on drug discovery, is positioning the milestone as part of a larger effort to change how medicines are developed. The immediate focus is practical rather than theoretical: Isomorphic Labs has anti-cancer drugs already in the pipeline and is preparing for clinical trials.
What Isomorphic Labs says is coming next
Colin Murdoch, President of Isomorphic Labs and Chief Business Officer at Deepmind, told Fortune that the company is near the point of entering human studies.
"We're staffing up now. We're getting very close," said Colin Murdoch, President of Isomorphic Labs and Chief Business Officer at Deepmind.
That statement gives the clearest signal in the source article about the company’s current stage. Isomorphic Labs is not only discussing AI-designed drugs as a research ambition; it is organizing for clinical work.
The source does not name a specific drug candidate, trial date, disease target beyond anti-cancer drugs, or clinical location. The key fact is narrower but significant: the company is preparing for its first clinical trials with drugs designed using AlphaFold-based AI models.
Why AlphaFold-based drug design matters here
Isomorphic Labs was created around the idea that AI can help reshape drug discovery. In this case, the company is using AlphaFold-based AI models as part of the design process for drug candidates.
The source frames the company’s goal as an attempt to overhaul a process described as traditionally slow and expensive. That matters because drug development is not presented as a simple software problem. The company’s next step is human trials, which means its AI-designed work must move from computational design and pipeline planning into clinical evaluation.
For readers following AI in medicine, this is the central point: Isomorphic Labs is nearing the moment when its AlphaFold-linked approach faces a real-world clinical checkpoint. The article does not claim that the drugs will succeed, and it does not report trial results. It reports preparation for first human trials.
The business backing behind the push
Isomorphic Labs is not moving alone. The source article says the company has signed agreements with Eli Lilly and Novartis. It also says that in 2025 the company closed a USD 600 million investment round led by Thrive Capital.
Those details show that the company’s AI drug discovery work has attracted both pharmaceutical partnerships and major investor support. The source does not describe the terms of the agreements with Eli Lilly and Novartis, so the important fact is their existence, not their scope.
The funding detail is also specific: USD 600 million, closed in 2025, led by Thrive Capital. For Isomorphic Labs, that capital sits behind a push toward clinical trials and a broader ambition to make AI central to the way drug candidates are designed.
The bigger ambition for AI in medicine
Murdoch also described a longer-term vision for the role of AI in drug development. The idea is not limited to improving one pipeline or supporting one class of medicines. Isomorphic Labs is aiming at a more sweeping model for designing drugs.
"One day we hope to be able to say— well, here's a disease, and then click a button and out pops the design for a drug to address that disease," Murdoch said.
That quote is aspirational, and the source presents it as a future goal rather than a current capability. The company is not reported to have reached a point where drug design is reduced to a button click. Instead, the quote explains the direction of travel: faster, more direct AI-assisted design for diseases.
The more immediate milestone is less dramatic but more concrete. Isomorphic Labs is staffing up and getting close to first clinical trials for drugs designed with AlphaFold-based AI models.
What to watch without overreading the news
The article’s facts support several careful takeaways:
- Isomorphic Labs is a Deepmind spin-off focused on drug discovery.
- The company is preparing for first human trials involving drugs designed with AlphaFold-based AI models.
- Anti-cancer drugs are already in the pipeline.
- It has signed agreements with Eli Lilly and Novartis.
- In 2025, it closed a USD 600 million investment round led by Thrive Capital.
What the source does not provide is just as important. It does not report clinical outcomes, trial timing, patient numbers, approval plans, or named drug candidates. Those gaps matter because they keep the story grounded.
For now, Isomorphic Labs is entering a more demanding phase. Its AlphaFold-based AI drug design work is moving toward human trials, where the company’s ambitions for AI in medicine will begin to meet clinical reality.